Table 4 SF-36 subsets (mean ± SD) at baseline and at week 16 (LOCF) including ANCOVA results from baseline to week 16 (LOCF) of ITT samples.
From: Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study
SF-36 subsets | Vardenafil (N = 21) | Placebo (N = 21) | |||||
|---|---|---|---|---|---|---|---|
Baseline | LOCF | Changes | Baseline | LOCF | Changes | p-valuea | |
Physical funct.b (85.7 ± 22.1) | 80.5 ± 19.9 | 74.3 ± 28.0 | -6.3 ± 15.0 | 77.0 ± 26.9 | 77.0 ± 27.6 | 0.0 ± 14.0 | 0.18 |
Role-physical (83.7 ± 31.7) | 58.8 ± 41.6 | 55.0 ± 44.9 | -3.8 ± 40.0 | 63.1 ± 44.4 | 51.2 ± 47.1 | -12 ± 33.2 | 0.53 |
Bodily pain (79.1 ± 27.4) | 60.1 ± 29.9 | 51.3 ± 31.4 | -8.8 ± 17.4 | 65.2 ± 28.4 | 62.9 ± 30.4 | -2.3 ± 19.9 | 0.21 |
General health (68.1 ± 20.2) | 59.5 ± 22.8 | 55.6 ± 25.4 | -3.8 ± 10.9 | 49.1 ± 20.3 | 48.0 ± 22.4 | -1.2 ± 12.0 | 0.52 |
Vitality (63.3 ± 18.5) | 55.3 ± 21.6 | 52.3 ± 22.6 | -3.0 ± 12.1 | 43.8 ± 20.1 | 42.5 ± 25.3 | -1.2 ± 13.9 | 0.75 |
Social funct.b (88.8 ± 18.4) | 73.2 ± 22.1 | 71.4 ± 24.4 | -1.8 ± 9.9 | 62.5 ± 32.8 | 64.9 ± 33.0 | 2.4 ± 24.2 | 0.70 |
Role-emotional (90.4 ± 25.6) | 63.1 ± 42.9 | 61.4 ± 46.2 | -1.7 ± 47.8 | 60.4 ± 43.0 | 54.0 ± 44.1 | -6.4 ± 41.8 | 0.64 |
Mental health (73.9 ± 16.4) | 67.0 ± 19.2 | 61.6 ± 21.6 | -5.4 ± 13.6 | 52.0 ± 20.4 | 51.0 ± 22.9 | -1.1 ± 14.3 | 0.59 |